On January 7, 2025 Esphera SynBio ("Esphera"), a synthetic biology company, reported the closing of a $2M USD seed financing round (Press release, Esphera SynBio, JAN 7, 2025, View Source [SID1234649480]). The financing builds on the Company’s advanced R&D activities and proceeds are directed at the identification of an initial cancer vaccine clinical candidate and general corporate purposes. Seed investors GKCC and FACIT supported the financing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Using synthetic biology, Esphera produces engineered exosomes through the expression of proprietary transgenes that serve as nanomedicines. Unlocking new possibilities in vaccine innovation, the company applies the technology platform for the development of therapeutics for cancer and infectious disease.
"This financing enables us to validate our vaccine platform and advance a potential best-in-class therapy for patients living with cancer," said Dr. Brian Lichty, co-founder and CEO of Esphera. "While our clear focus is on advancing toward future clinical trials, maximizing the broad potential of our technology will also necessitate the exploration of strategic partnerships."
Esphera’s innovative platform produces therapeutic nanomedicines that can act as powerful immunostimulants, delivering customized antigenic payloads to stimulate robust immune responses. These nanomedicines are designed to enhance the efficacy of vaccines, offering personalized solutions to combat infectious disease.
"With the fields of engineered exosomes and therapeutic vaccines undergoing rapid evolution, Esphera’s pioneering approach places the Company at the forefront of a transformative opportunity for patient care," said Dr. David O’Neill, Chair of the Board of Directors of Esphera and President of FACIT. "Esphera’s team of entrepreneurial scientific leaders has the experience required to build a strong pipeline of innovative therapeutics."
The Company is based on foundational intellectual property from the labs of Drs. Carolina Ilkow and John Bell at The Ottawa Hospital Research Institute and Dr. Lichty at McMaster University, and operates research facilities in Hamilton, Ontario and Ottawa, Ontario.